Statistics of Rare Events.
NEJM Evid
; 3(1): EVIDe2300303, 2024 Jan.
Article
em En
| MEDLINE
| ID: mdl-38320520
ABSTRACT
Rare events can sometime arise in clinical development of treatments. For example, CYPIDES was a single-arm study of the CYP11A1 inhibitor ODM-208 to treat metastatic prostate cancer.1 Preclinical testing of the compound identified elevated thyroid-stimulating hormone (TSH) and bilirubin in rats and dogs. Unusual findings in preclinical testing focus attention and magnify evidence if similar results occur in humans. By analogy, imagine a murder trial in which the only evidence against the defendant arose from a database search of DNA matching the partial profile found at the crime scene. Multiple people could match, so without other evidence, the perpetrator could be any of them.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Hipertireoidismo
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article